Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.
Euro Surveill
; 29(10)2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38456217
ABSTRACT
We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95%â¯CI 23-55) in 18-59-year-olds and 50% (95%â¯CI 44-56) in 60-85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (ORâ¯=â¯2.8; 95%â¯CI1.2-6.5) and, not statistically significant, from XBB.1.5 vaccination (ORâ¯=â¯1.5; 95%â¯CI0.8-2.6).
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Vacunas
/
COVID-19
Límite:
Adult
/
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
Euro Surveill
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
Año:
2024
Tipo del documento:
Article
País de afiliación:
Países Bajos